Management reported that growth product revenues increased 43% in the third quarter of 2026.
Qelbree prescriptions grew 18% compared to third quarter 2025.
Management targets $125 million in annual cost synergies from its merger.
On its third-quarter 2026 earnings call, held on Oct. 29, 2026, Supernus (NASDAQ:SUPN) announced that combined revenues for its key growth products rose 43% year over year. For long-term investors, sustained volume gains across core treatments demonstrate expanding market adoption and commercial execution.
Three takeaways from management highlight the strategic priorities for the business.
Supernus relies on its commercial growth lineup, including attention-deficit/hyperactivity disorder (ADHD) treatment Qelbree and postpartum depression medication ZURZUVAE, to drive top-line expansion as legacy treatments mature. Generating higher revenue across these central nervous system therapies validates long-term patient demand and justifies ongoing sales force investments.
For the third quarter of 2026, combined revenues of our growth products, Qelbree, ZURZUVAE, ONAPGO, and GOCOVRI increased by 43% compared to the same period last year.
-- Jack Khattar, Chief Executive Officer
Combining operations with Indivior Pharmaceuticals expands the commercial footprint across addiction and psychiatry while streamlining shared operations. Management targets $125 million in annual cost synergies, defined as operational savings from combining corporate and sales infrastructure, to enhance future profitability.
Integration planning has been underway, and we remain confident in capturing the $125 million of expected annual cost synergies that we previously discussed.
-- Jack Khattar, Chief Executive Officer
Parkinson's disease treatment ONAPGO received seven years of orphan drug exclusivity, a regulatory protection for specialized therapies, from the U.S. Food and Drug Administration (FDA). Securing intellectual protection and adding a second manufacturing source is expected to resolve prior supply bottlenecks to support steady prescription intake.
As we announced last week, the FDA has recognized seven years of orphan drug exclusivity for ONAPGO for the treatment of motor fluctuations in adults with advanced Parkinson's disease.
-- Jack Khattar, Chief Executive Officer
Commercial momentum is building across key treatments, and management is not hiding its satisfaction. Combining 11 differentiated medicines creates scale, while integration planning focuses on pricing discipline and operational execution.
The combined company will have a commercial portfolio of 11 differentiated medicines across psychiatry, neurology, and addiction with key growth products currently expected to continue growing well into the 2030s.
-- Jack Khattar, Chief Executive Officer
Steady cash flow generation provides the financial capacity to advance clinical research and expand market outreach.
We continue to generate strong cash flows behind the strength of our growth products and through the efficiency of our operations.
-- Jack Khattar, Chief Executive Officer
Before you buy stock in Supernus Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Supernus Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $305,941!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $771,325!*
Now, it’s worth noting Stock Advisor’s total average return is 719% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 22, 2026.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.